Application No.: 10/551,497 Docket No.: 17195/006001

AMENDMENTS TO THE CLAIMS

Please amend the claims as follows.

 (Currently Amended) A cardiomyopathy therapeutic agent that contains hepatocyte growth factor (HGF) and gelatin hydrogel, and wherein the gelatin hydrogel is selected such that it gradually releases HGF eentinued for about 4 weeks when used.

- 2. (Original) A cardiomyopathy therapeutic agent according to claim 1 wherein the gelatin has the following physical properties:
 - (1) an acidic gelatin obtained from collagen by alkaline hydrolysis treatment;
- (2) molecular weight under non-reducing conditions of SDS-PAGE of about 100,000 to about 200,000 daltons; and;
 - (3) zeta potential in aqueous solution of about -15 to about -020 mV.
- 3. 10. (Canceled)
- 11. (New) A method of treating cardiomyopathy comprising:

administering to a subject an effective amount of a cardiomyopathy the rapeutic agent of claim 1.

- 12. (New) The method of claim 11, wherein the gelatin has the following physical properties:
 - (1) an acidic gelatin obtained from collagen by alkaline hydrolysis treatment;

Application No.: 10/551,497 Docket No.: 17195/006001

(2) molecular weight under non-reducing conditions of SDS-PAGE of about 100,000 to about 200,000 daltons; and:

- (3) zeta potential in aqueous solution of about -15 to about -020 mV.
- 13. (New) The method of claim 11, wherein the cardiomyopathy is dilation cardiomyopathy.
- 14. (New) The method of claim 11, wherein the cardiomyopathy is hypertrophic cardiomyopathy.
- 15. (New) The method of claim 13, wherein the cardiomyopathy is idiopathic cardiomyopathy, primary cardiomyopathy or secondary cardiomyopathy.
- 16. (New) The method of claim 12, wherein the cardiomyopathy is dilation cardiomyopathy.
- 17. (New) The method of claim 12, wherein the cardiomyopathy is hypertrophic cardiomyopathy.
- 18. (New) The method of claim 16, wherein the cardiomyopathy is idiopathic cardiomyopathy, primary cardiomyopathy or secondary cardiomyopathy.